STUDY QUESTION: Do infertile women aged <38 years with quantitative evidence of diminished ovarian reserve and/or poor response to stimulation also exhibit poor oocyte quality as measured by blastulation rates, aneuploidy rates, and live birth rates?
Introduction
Diminished ovarian reserve (DOR) and poor response (PR) to stimulation are frequently encountered during infertility treatment (Devine et al., 2015) . However, characterizing the physiology underlying DOR has been challenging due to: (i) the lack of consensus regarding the diagnostic criteria for DOR/PR, (ii) the difficulty untangling agedependent (physiologic) from premature (nonphysiologic) declines in ovarian function (Sun et al., 2008) and (iii) disagreement regarding whether DOR/PR represents solely a quantitative or also qualitative decline in oocyte and embryo performance (Abdalla and Thum, 2004) .
Historically, assessments of ovarian reserve have been divided into two categories: pretreatment diagnostics and post-treatment review of response to stimulation. Pretreatment evaluations have been extensively studied and include basal FSH, inhibin B, ovarian volume, antral follicle count (AFC) and anti-mullerian hormone (AMH) levels (ASRM Practice Committee, 2012) . While each of these tests provides useful prognostic information, serum AMH has emerged as most widely used pretreatment diagnostic test due to its consistency within and between menstrual cycles and its high specificity for prognosticating a PR to stimulation (Hehenkamp et al., 2006; Dewailly et al., 2014) .
Completion of an ovarian stimulation cycle allows for posttreatment review of ovarian responsiveness. This 'stress test' provides valuable diagnostic information regarding the capacity of ovary to produce a sufficient number of oocytes and withstand the normal attrition observed at each developmental level in clinical ART. Indeed, it is well recognized that a PR to treatment portends a low likelihood of eventual success with autologous oocytes. This effect is exacerbated at more advanced ages (Kyrou et al., 2009) .
Despite the extensive literature examining clinical characteristics of patients with DOR or PR, there is still no consensus regarding whether their poor outcomes are solely the product of quantitative challenge presented by starting with fewer oocytes or whether there is an additional qualitative penalty. In other words, does an oocyte retrieved from a patient with DOR or PR also demonstrate a reduced capacity to meet developmental milestones and/or an increased likelihood of aneuploidy?
These questions have been partially addressed in a number of prior studies. Some investigations have concluded that pretreatment markers of DOR or post-treatment evidence of PR are associated with evidence of reduced oocyte quality. Indeed, evidence of DOR/PR has been associated with a decrease in embryo morphology grades and an increase in pregnancy loss, aneuploid miscarriages and viable aneuploid pregnancies (trisomy 13, 18, and 21) in young patients (Nasseri et al., 1999; van Montfrans et al., 1999; Silberstein et al., 2006; Haadsma et al. 2010; van der Stroom et al., 2011; Tarasconi et al., 2017) . However, other studies have demonstrated no association between DOR/PR and the same markers of oocyte quality (Thum et al., 2008; Thum and Abdalla, 2009; Ebner et al., 2006; Smeenk et al., 2007; Riggs et al., 2011) .
A major limitation of the current literature characterizing the oocyte quality in the context of DOR/PR is that both depletion of the follicular pool and a reduction in oocyte quality are physiologic events that accompany reproductive aging. The available studies do not address whether a premature depletion of the follicular pool (DOR/PR in younger patients) is also associated with accelerated reduction in oocyte quality. In other words, if patients exhibit a quantitative decline in ovarian reserve earlier than expected, do they also exhibit evidence of accelerated ovarian aging i.e. a qualitative decline as well (as evidenced by poor embryo development, aneuploidy risk and poor pregnancy outcomes).
To evaluate that question, we utilized a large retrospective database of patients <38 years old with pretreatment AMH values and available oocyte yields and compared markers of embryo quality between patients with DOR/PR and patients with normal results.
Materials and Methods
All autologous IVF cycles at a single institution (RMANJ, Basking Ridge, NJ, USA) between 2012 and 2016 were evaluated for inclusion in the analysis.
This time frame was chosen as all embryos were cultured to blastocyst at this clinic during the study period. No cleavage stage transfers were performed, regardless of the number of embryos present on Day 3. Thus, performance through blastulation could be observed of all embryos in the laboratory. Only the first cycle was included for each patient to eliminate previous failure bias. Patients with a history of ovarian surgery, chemotherapy or radiation exposure, fragile X premutation or abnormal karyotype were excluded from the analysis as our intention was to characterize patients with idiopathic reduction in ovarian reserve. Cases involving surgical sperm retrieval or chromosomal translocations were excluded given their propensity for poor blastocyst formation (Balaban et al., 2001; Munne et al., 1998) . This study was performed under institutional review board approval.
The stimulation approach was selected by each patient's primary physician and was based on ovarian reserve testing (AMH, AFC, day 3 FSH). All cycles included medications with FSH (recombinant or urinary) and LH activity (human menopausal gonadotropin or low-dose HCG). Starting doses for FSH varied from 150 to 450 IU per physician discretion. Doses were adjusted according to response to stimulation (as measured by ultrasounds and estradiol measurements). GnRH antagonist, agonist long down regulation, and microflare protocols were employed.
Only patients <38 years old at time oocyte retrieval were included in the analysis for multiple reasons. First, multiple studies have demonstrated that the rate of follicular depletion increases substantially when the number of primordial follicles falls below a critical threshold of 25,000 (Gougeon et al., 1994) . This number is reached at an average age of 37.5 years across multiple populations (Faddy et al., 1992) . As a result, the number of follicles reaching the growth phase in each menstrual cycle decreases substantially from around 45 in women <30 years old to approximately 6 in women over the age of 38 (Faddy and Gosden, 1995) . Thus, a quantitative decline in ovarian reserve is considered physiologic in women greater than 38 years old, whereas DOR prior to this age reflects a premature depletion.
Furthermore, large-scale studies of women pursuing preimplantation genetic testing for aneuploidy (PGT-A) demonstrate that aneuploidy sharply rises beginning at age 38 (Franasiak et al., 2014) . In addition, older patients have an increased risk of embryo arrest prior to the blastocyst stage (Dessolle et al., 2009; Thomas et al., 2010) . Thus, to attempt to determine if a quantitative decline in ovarian function was linked to a qualitative decline, we sought only to evaluate women with evidence of a premature or nonphysiologic depletion of the follicular pool (occurring at <38 years) to see if they also exhibited evidence of qualitative decline in oocyte function.
Precycle assessment ovarian reserve
In order to analyze the pretreatment evaluation of ovarian reserve, all patients with AMH levels drawn in the 6 months prior to initiating a stimulation cycle were included in the analysis. All AMH measurements were performed by an outside reference laboratory using Gen II ELISA Kit (A73818, Beckman Coulter, California, USA). The number of oocytes retrieved and the number of clinically usable blastocysts (at least a 4CC by modified Gardner grading) were recorded for each patient (Gardner et al., 2000) . All patients pursuing their first IVF cycle during the study period were included in this assessment (those planned for PGT-A and those planned for non-PGT-A cycles). All cycles that were canceled prior to retrieval were also recorded and compared. Finally, implantation rates (IRs, number of fetal heart beats per embryo transferred), live birth rates (LBRs, live births per embryo transfer procedure) and pregnancy loss rates (pregnancy loss after a positive beta-hCG) embryo transfers were compared between the groups.
In order to compare aneuploidy rates between the groups, a subgroup analysis was performed among only patients who underwent PGT-A. In order to be included in this group, at least one blastocyst must have been available for biopsy. For aneuploidy screening, diagnostic categories during the study period were only euploid or aneuploid (there were no segmental imbalance or mosaic aneuploidy diagnoses made). Finally, IRs, LBRs and pregnancy loss rates after euploid embryo transfers were compared between the groups.
Post-cycle diagnosis of PR
In order to assess ovarian reserve based on post-treatment parameters, the number of oocytes collected for each patient who proceeded to retrieval was recorded. Again, the number of oocytes retrieved and the number of clinically usable blastocysts (at least a 4CC by modified Gardner grading) were recorded for each patient. Pregnancy outcomes were also compared. Notably, this group included some patients who were not included in the precycle analysis as some patients did not have an AMH drawn in the 6 months prior to stimulation. Again, this assessment included all patients who completed retrieval (both patients planning PGT-A and patients not planning PGT-A).
Similarly, in order to compare aneuploidy rates between the groups, a subgroup analysis was performed among the patients who underwent PGT-A. The percentage of aneuploid blastocysts for each patient was recorded and compared. Pregnancy outcomes were also compared.
Definitions of study groups and control groups
In the precycle analysis, patients with AMH values in bottom 10th percentile were compared to patients in the interquartile range IQR; 25-75th percentile). The bottom 10th percentile was selected as the study group as these patients were most likely to manifest a true quantitative depletion of ovarian reserve. The IQR was selected as a control group as these patients were thought to best represent the typical state of physiologic ovarian reserve among infertility patients in this age-group. The highest quartile was intentionally not included given evidence that patients with high AMH levels are at increased risk of poor blastocyst development (likely due to the enrichment of PCOS patients in this category; Tal et al., 2014; Arce et al., 2014; Rubio et al., 2010) .
Similarly, in the postcycle analysis, patients with total number of oocytes retrieved in the bottom 10th percentile were compared to patients in the IQR (25-75th percentile).
Statistical analysis
Patient and cycle characteristics were compared between the <10th percentile and IQR for both precycle (AMH) and postcycle (oocyte yield) assessments. Continuous variables were compared using Student's t-test when data were normally distributed and by Mann-Whitney U when the data were not normally distributed. Chi-squared tests were used to compare proportions.
The primary outcomes were blastulation rate (defined as clinically usable blastocyst per 2PN), aneuploidy rate (determined by trophectoderm biopsy and whole chromosome aneuploidy assessment using a 24-chromosome qPCR-based platform) (Treff et al., 2012) and LBR per euploid blastocyst transfer. All patients (including patients utilizing PGT-A and patients not utilizing PGT-A) were included in the blastulation rate assessment, while only patients pursing PGT-A were included in the aneuploidy and live birth analyses. IRs and pregnancy loss rates were also compared.
For both precycle and postcycle analyses, a mixed effects model was employed to account for the effect of female age and to account for correlation between oocytes and embryos derived from the same patient. Using this model, adjusted odds ratios for blastulation, aneuploidy and live birth were calculated.
A subgroup analysis of patients who met the Bologna Criteria for PR to ovarian stimulation was also performed. As per the Bologna criteria, at least two of the following risk factors are required: (i) female age ≥40 years (or other risk factor for PR, such as genetic causes known to reduce follicle number), (ii) previous PR (≤3 oocytes) and (iii) abnormal ovarian reserve testing (AMH < 0.5 or AFC < 5-7). Given that patients over 38 and patients with genetic risk factors for DOR were excluded, the oocyte yield in the studied cycle could only be used to qualify patients for the Bologna criteria (as opposed to a prior history of PR to stimulation). As a result, patients in this analysis had ≤3 oocytes retrieved and had an AMH of <0.5. Blastulation rates, aneuploidy rates for PGT-A patients and LBRs per euploid blastoyst transfer were calculated. The rates of cancellation after retrieval and prior to transfer were also calculated
Results

Precycle comparison
Of the 3457 patients who met inclusion criteria and had AMH drawn within 6 months of their first IVF cycle start during the study period, the threshold for the <10th percentile was ≤0.5 ng/ml. A total of 345 patients had values in this range. The IQR for AMH was 1.1-4.5 ng/ml. A total of 1758 patients had AMH values in this range. Patients in the <10th percentile were slightly older and had higher basal FSH levels and lower AMH levels than patients in the IQR. They also had lower estradiol levels on the day of the LH surge and their cycles produced fewer oocytes and embryos. Patients in the <10th percentile had a lower LBR per stimulation start, likely due to greater likelihood of cycle cancellation both prior to oocyte retrieval due to PR and after oocyte retrieval due to the global arrest of embryos. However, the blastulation rate was no different between the groups. Furthermore, once a blastocyst was available for transfer, the LBR was no different between the groups (Table I) .
Among the subset of patients utilizing PGT-A, there were similar differences in patient characteristics and laboratory cycle outcomes. However, the aneuploidy rate was not different between the groups. The LBR, IR and pregnancy loss rate were also not different between the groups (Table I) .
A mixed effects model was performed to control for female age and to control for correlation between oocytes and embryos from the same patient cohort. After adjustment, a precycle AMH level in the <10th percentile did not decrease the odds of an embryo blastulating when compared to a precycle AMH level in the IQR. Among PGT-A patients, precycle AMH in the <10th percentile did not increase the odds of an embryo being aneuploid. Finally, a low AMH also did not decrease the odds of live birth after euploid embryo transfer. These data are depicted in Figure 1 .
A subset analysis was performed of patients with the highest AMH levels (75-100th percentile). The blastulation rate, aneuploidy rate and LBR for these patients were also no different to either the <10th percentile group or the IQR. Data for these patients are included in Supplementary Table S1 .
Postcycle comparison
Of the 5372 patients who met inclusion criteria and had their first oocyte retrieval during the study period, the threshold for the <10th percentile was ≤5 oocytes retrieved. A total of 535 patients had oocyte yields in this range. The IQR for yield was 10 to 21 oocytes. A total of 2675 patients had oocyte yields in this range. Patients with oocyte yield in the <10th percentile were slightly older and had higher basal FSH levels and lower AMH levels than patients in the IQR. They also had lower estradiol levels on the day of LH surge and their cycles produced fewer oocytes and embryos. The cycles were more likely to be canceled prior to embryo transfer due to global arrest of embryos. As a result, the overall LBR per retrieval was lower for patients in the <10th percentile. However, the overall blastulation rate was equivalent between the two groups. Furthermore, the LBR once a blastocyst was available for transfer was no different (Table II) .
Among the subset of patients utilizing PGT-A, there were similar differences in patient characteristics and laboratory cycle outcomes. However, the aneuploidy rate was not different between the groups. The LBR, IR and pregnancy loss rate were also not different between the groups (Table II) .
A mixed effects model was performed to control for female age and to control for correlation between embryos from the same patient cohort. The adjusted odds of an embryo blastulating were actually increased if it is originated from a cycle with oocyte yield in the <10th percentile compared to the IQR. Among PGT-A patients, embryos derived from oocytes in the <10th percentile of oocyte yield were at no increased risk of aneuploidy compared to those in the IQR. Finally, the odds of live birth was not decreased when the transferred embryo was originated from a retrieval with <10th percentile for oocyte yield. These data are depicted in Figure 2 .
A subset analysis was performed of patients with the highest oocyte yields (75th to 100th percentile). The blastulation rate, aneuploidy rate and LBR for these patients were also no different to either the <10th percentile group or the IQR. Data for these patients are included in Supplementary Table SII.
Bologna criteria subanalysis
A total of 45 patients met the Bologna criteria for PR to stimulation. The blastulation rate for this group was 51.3% (41/80). Of these, a total of 15 patients utilized PGT-A. The aneuploidy rate per embryo was 40% (8/20). While underpowered to make a comparison to the entire group, the blastulation and aneuploidy rates were consistent with the overall cohort (blastulation rate: 52.0% (17 238/33150); aneuploidy rate: 31.1% (2333/7511)). The cancellation rate due to global arrest of embryos was 31.1% (14/45) for patients meeting the Bologna criteria. This was predictably higher than that for the overall cohort rate (12.4% (394/3180)).
Discussion
PR to stimulation has long been known to significantly limit the success of assisted reproduction (Alviggi et al., 2016) . Given the attrition seen at each stage of the IVF process, the quantitative challenge presented by retrieving fewer oocytes is an obvious factor in the poor pregnancy rates in patients with DOR/PR. However, a number of studies have also suggested that patients with evidence of follicular depletion also exhibit reduced oocyte quality. This conclusion is logically given the fact that most patients with PR to stimulation are at an age where markers of oocyte quality are also compromised. However, most studies We sought to separate age-related diminution in oocyte quality by studying only patients <38 years old. This age was carefully selected given evidence from multiple studies that (i) average rate of follicular depletion, (ii) aneuploidy rate and (iii) and embryo arrest rate all increase significantly after age 38 (Faddy et al., 1992; Franasiak et al., 2014; Thomas et al., 2010) . Thus, if an accelerated deterioration in aneuploidy, blastulation and pregnancy outcomes occurred in parallel with DOR/PR in young patients, a unifying mechanism responsible for both qualitative and quantitative decline would be the likely culprit. However, if the blastulation, aneuploidy and pregnancy outcomes remained consistent with age-related controls with normal response, then the mechanisms governing follicular depletion and quality parameters would appear to be divergent.
The data presented here suggest that in patients <38 years old with either precycle evidence of DOR or PR to stimulation, there is no associated qualitative decline in oocyte performance. Thus, compared to normal responders, a fertlised oocyte retrieved from a young patient with DOR or PR is no less likely to form a quality blastocyst, be euploid or produce a live birth.
These data contrast with prior observations that concluded that aneuploid ongoing gestations and aneuploid miscarriages were more common in poor responders (Haadsma et al., 2010) . Furthermore, the only study to utilize trophectoderm biopsy and 24-chromosome screening platforms to address this issue at the embryonic level suggested that aneuploidy was increased in blastocysts of patients with DOR (Katz-Jaffe et al., 2013). However, patients in the DOR arm in this study were older than patients with normal ovarian reserve parameters, thus confounding the aneuploidy results. We also specifically included blastulation rates in the analysis, given evidence that Figure 1 Patients with precycle AMH levels <10th percentile have lower oocyte yields than those in the 25-75th percentile. However, on mixed effects model, a successfully fertilized oocyte derived from a patient with AMH in the <10th percentile has the same odds of forming a quality blastocyst, being euploid and producing a live birth after transfer of an euploid blastocyst. aneuploid embryos are more likely to arrest in extended culture (Vega et al., 2014) . Thus, while ploidy was not measured in the arrested embryos, equivalent blastulation in both groups is indicative of similar aneuploidy rates in arrested embryos as well. Including blastulation in the analysis also addressed nongenetic causes of embryo developmental competence that may be impacted by mechanisms of ovarian aging. However, no association was observed as blastulation rate was not different between the groups. The equivalent aneuploidy rate in DOR/PR patients to age-related controls also provides some insight into the biological processes mediating the age-related increase in meiotic errors in the oocyte. Indeed, there is still disagreement regarding whether segregation errors in oocytes are a reflection of the size of the remaining follicular pool or a function of cumulative, temporal exposure to oxidative damage and other stressors that predispose to aneuploidy (Nagaoka et al., 2012) . Our data do not support the 'first in, last out' hypothesis, whereby the last oocytes ovulated (irrespective of age) have the fewest recombination events and are thus at higher risk for segregation errors (Henderson and Edwards, 1968) . Instead, the normal age-related aneuploidy rate and clinical performance of oocytes in these DOR/PR patients suggest that errors are more a function of time-related damage or deterioration in mechanisms responsible for maintaining cohesion between sister chromatids (such as cohesins) (Liu and Keefe, 2008; Chiang et al., 2011; Jeffreys et al., 2003) .
The ultimate test of oocyte and embryo quality is establishment of a healthy pregnancy that progresses to delivery. While prior studies have reported an age-independent association between DOR/PR and decreased IRs (El Toukhy et al., 2002) and increased miscarriage rates (Levi et al., 2001) , we found no such effect. Our observation that an oocyte retrieved from a DOR patient performs similarly to that from age-matched controls has important implications for cycle planning. Many patients bank embryos according to clinic-based projections regarding how many embryos are needed for a patient's ideal family size. While prior literature has implied that more embryos were required for each live birth in these patients, our data suggest that ovarian reserve and response do not impact the anticipated competence of a given embryo. This is a valuable information for pretreatment counseling.
While these data provide the largest experience comparing extended culture, aneuploidy screening and pregnancy outcomes between DOR/PR patients and normal responders, there are limitations given the retrospective nature of the analysis. Some patients in the PR group may have done better in subsequent stimulations with different protocols and thus may have no longer met criteria for PR. Indeed, some of these patients may have been included in the 'poor responder' group but in fact behaved more similarly to their agematched controls in subsequent cycles. Furthermore, given the limited number of growing follicles in DOR/PR patients, retrieval timing in patients with fewer follicles may have produced better average oocyte developmental competence per follicle.
It is also important to note that the average duration of infertility in the patients in this study was less than 12 months (the duration required to meet the ICMART/WHO definition of infertility) (ZegersHochschild et al., 2009). Thus, it is possible that the favorable blastulation rate, euploidy rate and LBRs described in these patients may be at least partially reflect the fact that some better prognosis patients were included in the DOR/PR groups. This is especially important in the precycle assessment, given evidence that AMH alone is poorly predictive of fecundity (Steiner et al., 2017) . However, a subset analysis of patients with more than 12 months of infertility demonstrated similar outcomes to the entire population analyzed here, so any confounding influence of including women with less than 12 months of infertility appears relatively limited.
Another limitation of this study is the inability to decipher whether or not patients were on oral contraceptive pills (OCPs) at the time their AMH level was drawn. We included all patients who had an Figure 2 Despite being derived from a cycle with significantly poorer response, an oocyte retrieved from a cycle with an oocyte yield in the <10th percentile has the same odds of being euploid and producing a live birth after transfer of an euploid embryo, on mixed effects model. The adjusted odds of forming a high quality blastocyst were higher for a successfully fertilized oocyte retrieved in a PR cycle.
AMH drawn within 6 months of their cycle starts, but we did not have any information regarding whether or not they were on OCPs at that time. It is possible that the AMH of some patients in the <10th percentile group may have been influenced by suppressive effect of OCPs. This may also partially explain why some patients in the low AMH group had more oocytes retrieved than expected. However, this may also simply reflect the limitations of AMH to prognosticate stimulation outcomes in all patients. These are only some examples of potential confounders that may influence our retrospective data. There are almost certainly others that are present but difficult to control for in this retrospective study. Prospective studies will be required to better elucidate the issues addressed here.
Another caveat to mention is the fact that results from the blastulation rate analysis included both PGT-A and non-PGT-A patients. In contrast, the aneuploidy rate calculation was only able to be performed for patients who pursued PGT-A. As a result, the population of patients was slightly different for the blastulation and aneuploidy evaluations. This was carefully considered by the authors, and we thought that including as many patients as possible in the blastulation rate analysis was preferable in order to improve external validity to our data. Had we limited this analysis to only PGT-A patients, it would have been less clear if these findings were applicable to patients not pursuing aneuploidy screening. As a result, we thought on balance it was more valuable to providers to include all relevant patients in the blastulation analysis than including only one study population and limit the applicability to other practice preferences.
Finally, age-specific percentiles for AMH or oocyte yield were not calculated for each age category in the <38-year old range. It is almost certain that the bottom 10th percentile is different for a patient in her mid-20s than a patient in her mid-30s. However, maintaining power to perform comparisons becomes challenging when creating further subcategories of patients who already have a relatively rare outcome (severe DOR in a young patient). Furthermore, the AMH threshold used for the entire population of patients (0.5 ng/ml) represented the 12th percentile for the oldest category of patients in the group (age 35-37.9 years). Thus, even at this threshold, older patients in the study group still represented patients with significantly DOR testing than the vast majority of their age-matched controls. The differences in percentiles according to age were also accounted for in the mixed effects model. Despite these potential limitations, these data provide evidence from a large cohort that the lower LBR observed in young poor responders is due to the quantitative challenge of starting with fewer oocytes and not due to an additional qualitative penalty of poor oocyte development in the laboratory or after transfer.
